Levine LA, Cuzin B, Mark S et al: Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's diease: a phase 3 open-label study
Key Takeaways Tirzepatide (Zepbound) produces greater average weight loss than semaglutide (Wegovy) across both clinical trials and the first direct head-to-head comparison, 20.9% versus 14.9% in separate Phase 3 trials, and 20.2% versus 13.7% in the SURMOUNT-5 trial published in the New England Journal of Medicine
About 72% of medication administration errors pursuant to a faulty medication reconciliation exercise resulted in patients receiving the wrong release dose formulation (i.e., immediate release as opposed to extended release)
Ir para o contedo principal Ir para o menu de navegao principal Ir para o rodap Open Menu Artigos Edio atual Edies anteriores Sobre Sobre a Revista Comisso Editorial Publicaes de eventos Declarao de Privacidade Contato Instrues aos Autores Cadastro Acesso Buscar Cadastro Acesso Idioma Portugus (Brasil) English Enviar Submisso Enviar Submisso
Record the Injection Note the medication, dose, date, time, and injection location
This complementary action means taking both can provide more comprehensive antioxidant coverage than either alone